|
06/19/2008 05:00 AM |
|
Release of Generic Lipitor Is Delayed |
 The settlement of a patent dispute over the blockbuster cholesterol drug will delay the release of generic versions in the United States until 2011.
|
|
03/06/2008 05:00 AM |
|
LETTER; Those Lipitor Ads: Dr. Jarvik Makes His Case |
Letter from Dr Robert Jarvik, inventor of artificial heart, defends his decision to act as spokesman for cholesterol-lowering drug, Lipitor (Feb 27 editorial)
|
|
03/04/2008 05:00 AM |
|
Drug Pitchmen: Actor, Doctor or Pfizer’s Option |
 Surely the best message we can derive from the Dr. Robert Jarvik episode is that it may be time to rethink the advertising of prescription drugs.
|
|
02/27/2008 05:00 AM |
|
Lipitor’s Pitchman Gets the Boot |
Pfizer’s recent decision to drop Dr. Robert Jarvik was a telling reminder that consumers need to take what they see and hear with a large grain of skepticism.
|
|
02/26/2008 05:00 AM |
|
Pfizer to End Lipitor Ads by Jarvik |
Criticized that its ads are misleading, Pfizer said it would end a campaign using the artificial heart pioneer Robert Jarvik as a spokesman for its cholesterol drug Lipitor.
|
|
02/08/2008 05:00 AM |
|
Committee Investigates Ad Tactics for Lipitor |
 A Congressional committee wants information about people who might have served as stunt doubles for Dr. Robert Jarvik in televised ads.
|
|
02/07/2008 05:00 AM |
|
Drug Ads Raise Questions for Heart Pioneer |
 Dr. Robert Jarvik’s appearance in television ads for Lipitor has helped rekindle a smoldering debate.
|
|
01/17/2008 05:00 AM |
|
Cholesterol As a Danger Has Skeptics |
Some prominent cardiologists says results of two recent clinical trials have raised serious questions about theory that lowering cholesterol is always beneficial, and value of cholesterol-lowering drugs Zetia and Vytorin; they say other new cholesterol-fighting drugs, including one that Merck hopes to begin selling this year, may also require closer scrutiny; cardiologist Dr Eric J Topol says idea that lowering LDL will make people better is too simplistic; for patients and drug companies, stak...
|
|
01/15/2008 05:00 AM |
|
Study Reveals Doubt on Drug for Cholesterol |
A clinical trial of Zetia, a widely used cholesterol drug, has raised questions about its effectiveness and the behavior of pharmaceutical companies that conducted the study.
|
|
12/21/2007 05:00 AM |
|
Data About Zetia Risks Was Not Fully Revealed |
New evidence shows that drug makers Merck and Schering-Plough never published several studies that raised questions about a cholesterol drug’s risks to the liver.
|
|
11/03/2007 04:00 AM |
|
Maker of Lipitor Digs in to Fight Generic Rival |
Many patients on the cholesterol drug are switching to a cheaper alternative, but Pfizer is not letting its flagship product go down without a fight.
|
|
10/19/2007 05:00 AM |
|
Weak Sales Prompt Pfizer to Cancel Diabetes Drug |
The discontinuation of Exubera, an inhaled insulin, is another black eye for Pfizer, the world’s biggest drug company, which has recently sustained a series of reversals.
|
|
07/19/2007 05:00 AM |
|
Pfizer Earnings Show a Decline As Sales Slow |
Pfizer Inc reports lower-than-expected earnings in second quarter on competition from generics and surprisingly 13 percent decline in sales of its best-selling drug Lipitor; earned $1.27 billion, compared with $2.42 billion year earlier; global company revenue fell 6 percent, to $11.08 billion
|
|
03/27/2007 05:00 AM |
|
Merck and Schering-Plough Plan Another Cholesterol Drug |
The two companies will develop a medicine combining their Zetia with Pfizer’s blockbuster Lipitor.
|
|
01/27/2007 05:00 AM |
|
The Dangers of Swinging for the Fences |
 That era when Pfizer was the king of the hill wasn’t some distant age it was just maybe three or four years ago. Oh, how the mighty have fallen!
|
